Search Clinical Trials
Before medications are approved by the U.S. Food and Drug Administration (FDA) or before certain therapy methods are widely accepted as effective, they are tested on people who volunteer to participate in a clinical trial.
Organizations across the country are looking for people like you to take part in their research studies. The list of studies below have been selected from ClinicalTrials.gov based on their inclusion of one or more of the following terms: anxiety disorders, depression, OCD, PTSD, and bipolar disorder.
The Anxiety and Depression Association of America (ADAA) is supportive of research that is conducted through clinical trials. Participating in research can potentially help change the mental health outcomes for you and others who suffer anxiety, depression, and related disorders. You may learn about new interventions/treatments that are being considered. This website page is brought to you in partnership with ResearchMatch.
Sponsor Condition of Interest |
---|
Development of Magnetic Resonance Imaging Techniques for Studying Mood and Anxiety Disorders
National Institute of Mental Health (NIMH)
Mood Disorders
Anxiety Disorders
This study is intended to help develop new MRI imaging techniques for studying mood and
anxiety disorders. Researchers believe that depression and anxiety disorders may cause
structural and functional changes in the brain. This study will optimize the way MRI
scans are collected to look at brain structure... expand
This study is intended to help develop new MRI imaging techniques for studying mood and anxiety disorders. Researchers believe that depression and anxiety disorders may cause structural and functional changes in the brain. This study will optimize the way MRI scans are collected to look at brain structure and examine how the brain behaves while subjects perform particular tasks. Healthy volunteers and individuals with major depressive disorder may be eligible for this study. Participants undergo magnetic resonance imaging (MRI) and neuropsychological testing. : Individuals will be asked to participate in an MRI study on one of several scanners. The scanner used will measure blood flow in the brain, concentrations of certain chemicals in the brain, or magnetic properties of the brain. The scan may involve They watching a screen presenting images or doing a task in which they respond to pictures or sounds. Participants may be asked to return for additional scans. The study also involves neuropsychological tests, which assess cognitive performance. Often, people with mood disorders have subtle changes in performance on these tests that allow researchers to pinpoint where brain abnormalities occur. Before the tests can be used in patients, they must be validated by using healthy subjects. These tests are presented either orally, in written form, or on a computer. Type: Observational Start Date: Dec 2006 |
Concurrent fMRI-guided rTMS and Cognitive Therapy for the Treatment of Major Depressive Episodes
National Institute of Mental Health (NIMH)
Major Depressive Disorder
Background:
Repetitive transcranial magnetic stimulation (rTMS) is a treatment for depression. It
stimulates the brain. Researchers want to see if using magnetic resonance imaging (MRI)
scans helps locate the best area for rTMS in each person. They also want to find other
ways to make it more effective.
Objective:
To... expand
Background: Repetitive transcranial magnetic stimulation (rTMS) is a treatment for depression. It stimulates the brain. Researchers want to see if using magnetic resonance imaging (MRI) scans helps locate the best area for rTMS in each person. They also want to find other ways to make it more effective. Objective: To study the effects of combining MRI- guided transcranial magnetic stimulation (TMS) and talk therapy on the brain in people with depression. Eligibility: Adults ages 18-75 with a major depressive disorder and current depression. If taking an antidepressant, should have been doing so for at least 4 weeks. Design: Participants will be screened with medical and psychiatric history, psychiatric evaluation, physical exam, and blood and urine tests. Phase 1 is 1-4 visits in 1 week. Participants will have: - Brain MRI. Participants will lie on a table in a scanner. - Questions about their medical history and psychology symptoms - Tests of mood and thinking - Tests of brain activity. Participants may do tasks during these tests: - A cone with magnetic detectors is put on the head. - A cap with electrodes is put on the scalp. - TMS. A brief electrical current passes through a wire coil on the scalp. - A metal disk will be placed on the arm. A nerve will be stimulated with a small electrical shock. Phase 2 is about 6 to 7 weeks. - There will be 30 daily sessions of combined therapy and repetitive TMS (rTMS) for 6 weeks. - Participants will receive rTMS and another therapy by computer. - For rTMS, repeated pulses will pass through the coil. - This is followed by up to 3 additional visits, when: - Participants will repeat Phase 1 tests - Participants will rate their depression symptoms. Phase 3 is 3 visits over 3 months. Participants will rate their depression symptoms and repeat some of the previous questionnaires and tests of mood and thinking. Type: Interventional Start Date: May 2018 |
Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients
Jina Pharmaceuticals Inc.
Bipolar 1 Disorder
Bipolar disorder (BPD) is a chronic debilitating illness characterized by drastic swings
in mood, energy and functional ability that affects the adult population. Endoxifen is an
active metabolite of the marketed drug Tamoxifen and the present study aims to evaluate
the efficacy and safety of 8 mg... expand
Bipolar disorder (BPD) is a chronic debilitating illness characterized by drastic swings in mood, energy and functional ability that affects the adult population. Endoxifen is an active metabolite of the marketed drug Tamoxifen and the present study aims to evaluate the efficacy and safety of 8 mg endoxifen in the Bipolar I disorder patient population compared to a placebo arm. Endoxifen will be compared to a placebo to demonstrate that the test product is active and to establish that the study is sufficiently sensitive to detect differences between the investigational products. Thus, Endoxifen will be compared to placebo to demonstrate that the test product is safe and active. Type: Interventional Start Date: Mar 2024 |
A Study to Explore the Effect of SP-624 on Brain Network Analytics in Healthy Adults and Adults With...
Sirtsei Pharmaceuticals, Inc.
Major Depressive Disorder
Depression
Healthy
The main goal of this clinical trial is to learn if the active study drug (code name:
SP-624) has any effect on the electrical activity of the brain in adult healthy
volunteers and in adults with major depression. Another goal of the study is to learn if
SP-624 improves memory and learning in adults... expand
The main goal of this clinical trial is to learn if the active study drug (code name: SP-624) has any effect on the electrical activity of the brain in adult healthy volunteers and in adults with major depression. Another goal of the study is to learn if SP-624 improves memory and learning in adults with major depression. The study will also provide additional information on the safety of SP-624 and how well it is tolerated in adult healthy volunteers and adults with major depression. Researchers will compare SP-624 to a placebo (a look-alike substance that contains no drug) to see if SP-624 has any effect on study tests. Study participants will: Take capsules of study drug (SP-624 or a placebo) once daily for 2 weeks; visit the clinic at Screening, Day 1 (first dose of study drug), and Day 15 (last dose of study drug) for checkups and tests; and have phone call check-ups on Day 7 and about 1 week after the last dose of study drug. Type: Interventional Start Date: Aug 2024 |
A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder...
Janssen Research & Development, LLC
Depressive Disorder, Major
Anhedonia
The purpose of this study is to evaluate how well aticaprant works as compared with
placebo when given along with an antidepressant therapy in improving the depressive
symptoms in adult participants with major depressive disorder (MDD) with moderate to
severe anhedonia (ANH+) who have not responded... expand
The purpose of this study is to evaluate how well aticaprant works as compared with placebo when given along with an antidepressant therapy in improving the depressive symptoms in adult participants with major depressive disorder (MDD) with moderate to severe anhedonia (ANH+) who have not responded well to current antidepressant therapy with a selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor (SSRI or SNRI). Type: Interventional Start Date: Jun 2024 |
New Investigational Stimulation Protocol for Treatment of Major Depression Disorder (MDD)
Brainsway
Major Depressive Disorder
The BrainsWay Deep Transcranial Magnetic Stimulation (Depp TMS) device is intended for
the treatment of depressive episodes in patients suffering from Major Depressive Disorder
(MDD). The device technology is based on the application of deep brain TMS by means of
repetitive pulse trains at a determined... expand
The BrainsWay Deep Transcranial Magnetic Stimulation (Depp TMS) device is intended for the treatment of depressive episodes in patients suffering from Major Depressive Disorder (MDD). The device technology is based on the application of deep brain TMS by means of repetitive pulse trains at a determined frequency. The purpose of the current study is to evaluate the safety and effectiveness of a new investigational stimulation protocol delivered with the BrainsWay Deep TMS device, for the treatment of MDD, demonstrating that it is non-inferior to the current standard-of-care stimulation protocol, in a randomized, controlled study. Type: Interventional Start Date: Apr 2024 |
Cognitive Behavioral and Faith Fellowship to Improve Thy Health
University of Wisconsin, Madison
Depression
Investigators will examine the efficacy of a faith-based depression intervention, in
reducing symptoms of depression among African American adults in Wisconsin. Twelve church
groups, each with 10 people (N=120) will be invited to participate. This intervention
will be the first evidence-based, faith-based... expand
Investigators will examine the efficacy of a faith-based depression intervention, in reducing symptoms of depression among African American adults in Wisconsin. Twelve church groups, each with 10 people (N=120) will be invited to participate. This intervention will be the first evidence-based, faith-based intervention designed for African Americans if validated. Type: Interventional Start Date: Oct 2024 |
Tracking Brain Biomarkers and Renormalization Associated With Antidepressant Transcranial Magnetic Stimulation...
Medical University of South Carolina
Major Depressive Disorder
This study will attempt to use magnetic resonance imaging (MRI) to take a picture of the
brain to learn about changes that occur in the brain during Transcranial Magnetic
Stimulation (TMS) in people receiving this treatment for depression. expand
This study will attempt to use magnetic resonance imaging (MRI) to take a picture of the brain to learn about changes that occur in the brain during Transcranial Magnetic Stimulation (TMS) in people receiving this treatment for depression. Type: Observational Start Date: Apr 2023 |
Transcranial Magnetic Stimulation for MCI
Medical University of South Carolina
Mild Cognitive Impairment
Depression
The goal of this phase II study is to establish the dose-response curves of a safe and
clinically feasible non-invasive brain stimulation technique (accelerated Transcranial
Magnetic Stimulation (TMS)) to improve both depression and cognitive function in Mild
Cognitive Impairment (MCI) patients with... expand
The goal of this phase II study is to establish the dose-response curves of a safe and clinically feasible non-invasive brain stimulation technique (accelerated Transcranial Magnetic Stimulation (TMS)) to improve both depression and cognitive function in Mild Cognitive Impairment (MCI) patients with comorbid depression. It is known that TMS can effectively treat depression. Identifying the right dose of accelerated TMS in MCI patients is necessary prior to designing subsequent trials to determine efficacy. These results will inform future clinical trials of accelerated TMS for MCI, with the long-term goal of developing an efficacious treatment to prevent dementia. Type: Interventional Start Date: Jun 2024 |
Novel Mental Health Therapies to Improve Military Readiness
David Moss
Anxiety
Alpha Stim
Cranial Electrotherapy Stimulation
Cognitive Behavioral Therapy
Heart Rate Variability
To evaluate the efficacy of CES as a therapy to treat and mitigate symptoms of
generalized anxiety in DoD beneficiaries in a prospective clinical trial and compare this
to sham (placebo) CES. expand
To evaluate the efficacy of CES as a therapy to treat and mitigate symptoms of generalized anxiety in DoD beneficiaries in a prospective clinical trial and compare this to sham (placebo) CES. Type: Interventional Start Date: Jan 2024 |
A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to...
Janssen Research & Development, LLC
Depressive Disorder, Major
The purpose of this study is to assess the socio-demographic, disease-related and
treatment-related characteristics, and the standard of care (SOC) treatment patterns of
participants with major depressive disorder (MDD) with anhedonia with inadequate response
to their current antidepressant treatments... expand
The purpose of this study is to assess the socio-demographic, disease-related and treatment-related characteristics, and the standard of care (SOC) treatment patterns of participants with major depressive disorder (MDD) with anhedonia with inadequate response to their current antidepressant treatments and treated according to the standard of care treatment. Type: Observational Start Date: Apr 2023 |
DBS for TRD with the Medtronic Percept PC
Helen Mayberg, MD
Major Depressive Disorder
Treatment Resistant Depression
Of the estimated 30 million Americans who suffer from Major Depressive Disorder,
approximately 10% are considered treatment resistant. Deep brain stimulation (DBS) to a
region of the brain called the subcallosal cingulate (SCC) is an emerging strategy for
treatment resistant depression (TRD), which... expand
Of the estimated 30 million Americans who suffer from Major Depressive Disorder, approximately 10% are considered treatment resistant. Deep brain stimulation (DBS) to a region of the brain called the subcallosal cingulate (SCC) is an emerging strategy for treatment resistant depression (TRD), which involves placement of electrodes in a specific region of the brain and stimulating that area with electricity. This is believed to reset the brain network responsible for symptoms and results in a significant antidepressant response. A series of open-label studies have demonstrated sustained, long-term antidepressant effects in 40-60% of patients who received this treatment. A challenge to the effective dissemination of this fledgling treatment is the absence of biomarkers (objective, measureable indications of the state of the body and brain) to guide device placement and select stimulation parameters during follow-up care. By using a DBS device called the Percept PC (Medtronic, Inc) which has the ability to both deliver stimulation to and record electrical signals directly from the brain, this study aims to identify changes in local field potentials (LFPs), specific electrical signals that are thought to represent how the brain communicates information from one region to another, to see how this relates to DBS parameter settings and patient depressive symptomatology. The goal of this study is to study LFPs before and during active DBS stimulation to identify changes that correlate with the antidepressant effects of SCC DBS. The study team will recruit 10 patients with TRD and implant them with the Percept PC system. Participants will be asked to complete short questionnaires and collect LFP data twice daily for the first year of the study, as well as have weekly in person research procedures and assessments with the study team for up to one year. These include meetings with the study psychiatrist, psychologist, symptom ratings, and movement, voice, and video recordings. A brief discontinuation experiment will be conducted after 6 months of stimulation, in which the stimulation will be turned off and patterns of LFP changes will be recorded. The entire study is expected to last about 5 years, parcellated into several study phases. All participants are required to live in the New York metropolitan area for the first several months of the study. Type: Interventional Start Date: Mar 2023 |
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD
COMPASS Pathways
Treatment Resistant Depression
Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with
treatment-resistant depression (TRD) expand
Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD) Type: Interventional Start Date: Feb 2023 |
Preventing the Development of Chronic Pain: Treating PTSD at Acute Pain Onset
Rush University Medical Center
PTSD
Chronic Pain
Although most people recover from acute pain (such as pain caused by injury, surgery,
repetitive motion, or unknown causes), many people do not fully recover and will
experience chronic pain. Untreated posttraumatic stress disorder (PTSD) appears to be a
key risk factor for the transition from acute... expand
Although most people recover from acute pain (such as pain caused by injury, surgery, repetitive motion, or unknown causes), many people do not fully recover and will experience chronic pain. Untreated posttraumatic stress disorder (PTSD) appears to be a key risk factor for the transition from acute pain to chronic pain. However, few published studies have addressed the issue of preventing the transition from acute to chronic pain via PTSD reduction. This project will aim to test whether trauma-related PTSD symptoms can be reduced using either Stellate Ganglion Block (SGB) treatment or Cognitive Processing Therapy (CPT), and whether reducing PTSD symptoms can prevent the transition from non-injury based acute pain to chronic pain. Type: Interventional Start Date: Sep 2023 |
Engagement in CHildhood-Onset Systemic Lupus
Montefiore Medical Center
Lupus Erythematosus, Systemic
Depression
The goal of this observational (Aim 1) and pilot study (Aim 2) is to better understand
how depression symptoms may contribute to how well adolescent and young adults with lupus
follow-up with their lupus clinical care. The main questions the overall study attempts
to answer are:
1. Whether anhedonia... expand
The goal of this observational (Aim 1) and pilot study (Aim 2) is to better understand how depression symptoms may contribute to how well adolescent and young adults with lupus follow-up with their lupus clinical care. The main questions the overall study attempts to answer are: 1. Whether anhedonia (a core symptom of depression) predicts disengagement in care 2. Whether a patient-tailored mobile health application built to improve both engagement in care and depression symptoms will be feasible and acceptable to adolescents and young adults with lupus. Participants with systemic lupus, ages 15-24 from the Bronx, New York will be asked to complete questionnaires; some will be asked to participate in focus groups to help adapt the mobile health app; participants will also be invited to join a pilot study to try the mobile health app for 6 months and answer questionnaires to document the experience. Type: Interventional Start Date: May 2024 |
Modulating Exercise Dosage to Improve Concussion Recovery
University of Colorado, Denver
Concussion, Brain
Treatment
Aerobic Exercise
Inflammation
Depression, Anxiety
Aerobic exercise has emerged as an effective treatment to reduce sport-related concussion
symptom severity, yet existing work lacks rigor regarding the precise exercise volume and
intensity required to elicit therapeutic effects, how exercise can alter
concussion-related pathophysiology, and whether... expand
Aerobic exercise has emerged as an effective treatment to reduce sport-related concussion symptom severity, yet existing work lacks rigor regarding the precise exercise volume and intensity required to elicit therapeutic effects, how exercise can alter concussion-related pathophysiology, and whether exercise can prevent the development of secondary sequelae. Our objective is to examine if a high dose exercise program (higher volume than currently prescribed at an individualized, safe intensity level) initiated within 14 days of concussion results in faster symptom resolution, altered physiological function, or reduced secondary sequalae. Findings from this research will lead to more rigorous and precise rehabilitation guidelines and improved understanding about how exercise affects neurophysiological function among adolescents with concussion. Type: Interventional Start Date: Aug 2022 |
Behavioral Activation Teletherapy to Increase Physical Activity
University of Texas Southwestern Medical Center
Depression
Depressive Disorder
Depressive Symptoms
Depressive Episode
This is a pilot study of acceptability, feasibility, and preliminary efficacy of a brief,
10-session Behavioral Activation intervention delivered via teletherapy to increase
physical activity and treat depressive symptoms. expand
This is a pilot study of acceptability, feasibility, and preliminary efficacy of a brief, 10-session Behavioral Activation intervention delivered via teletherapy to increase physical activity and treat depressive symptoms. Type: Interventional Start Date: Aug 2021 |
Evaluation of the Genetics of Bipolar Disorder
National Institute of Mental Health (NIMH)
Bipolar Disorder
This study looks to identify genes that may affect a person's chances of developing
bipolar disorder (BP) and related conditions. expand
This study looks to identify genes that may affect a person's chances of developing bipolar disorder (BP) and related conditions. Type: Observational Start Date: Aug 1994 |
Prediction of Anxiety and Memory State
Columbia University
Anxiety
Memory
Epilepsy
The purpose of this study is to look at how signals in the brain, body, and behavior
relate to anxiety and memory function. This project seeks to develop the CAMERA
(Context-Aware Multimodal Ecological Research and Assessment) platform, a
state-of-the-art open multimodal hardware/software system for... expand
The purpose of this study is to look at how signals in the brain, body, and behavior relate to anxiety and memory function. This project seeks to develop the CAMERA (Context-Aware Multimodal Ecological Research and Assessment) platform, a state-of-the-art open multimodal hardware/software system for measuring human brain-behavior relationships. The R61 portion of the project is designed to develop the CAMERA platform, which will use multimodal, passive sensor data to predict anxiety-memory state in patients undergoing inpatient monitoring with intracranial electrodes for clinical epilepsy, as well as to build CAMERA's passive data framework and active data framework. Type: Observational Start Date: Jul 2024 |
Suicide Specific Rumination in Veterans
VA Office of Research and Development
Depression
Suicide
Mood Disorders
Few treatments target core features of suicidal thoughts and behaviors in Veterans.
Real-time functional magnetic resonance imaging neurofeedback can provide information
regarding brain activation associated with suicide-specific rumination, defined as a
"repetitive mental fixation on one's suicidal... expand
Few treatments target core features of suicidal thoughts and behaviors in Veterans. Real-time functional magnetic resonance imaging neurofeedback can provide information regarding brain activation associated with suicide-specific rumination, defined as a "repetitive mental fixation on one's suicidal thoughts and intentions." The goal of this feasibility study is for Veterans to learn strategies for modulating activity within brain regions that have been demonstrated to contribute to the maintenance of rumination, as they receive neurofeedback feedback signals from the brain. Type: Interventional Start Date: Aug 2024 |
SAINT for MDD in an Inpatient Setting Follow-on
Magnus Medical
Major Depressive Disorder
Major Depressive Episode
Suicidal Ideation
Randomized, multi-site, sham-controlled, double-blinded study expand
Randomized, multi-site, sham-controlled, double-blinded study Type: Interventional Start Date: Jun 2024 |
Observational Study of Oral Cariprazine Capsules to Assess Change in Disease Activity in Adult Participants...
AbbVie
Bipolar I Disorder
Bipolar I disorder (BP-I) is a common, chronic, and disabling mental illness with
significant morbidity and mortality defined by episodes of mania and depression (or
symptoms of both at once, known as mixed features). This prospective, observational study
will examine effectiveness, functioning and... expand
Bipolar I disorder (BP-I) is a common, chronic, and disabling mental illness with significant morbidity and mortality defined by episodes of mania and depression (or symptoms of both at once, known as mixed features). This prospective, observational study will examine effectiveness, functioning and quality of life outcomes in adult patients with BP-I experiencing a major depressive episode (with or without mixed features) requiring treatment and initiating treatment with cariprazine. It will examine outcomes of cariprazine treatment in a real-world setting in patients with BP-I commonly seen in clinical practices. Cariprazine (Vraylar) is a medication indicated in the United States and Canada to treat adult patients experiencing manic, mixed or depressive episodes associated with BP-I. This study plans to enroll approximately 170 adult patients with BP-I from the United States and Canada. Cariprazine should be prescribed by the physician under the usual and customary practice of physician prescription. The decision to initiate treatment with cariprazine should be made prior to, and independently from, the patient's decision to participate in the study. Participants will receive cariprazine as prescribed by their physician. Observational data will be collected during visits which should align to routine standard of care for a duration of up to 24 weeks. Type: Observational Start Date: Apr 2024 |
Transcranial Direct Current Stimulation (tDCS) As an Adjunctive Treatment for Treatment Resistant Depression...
Mayo Clinic
Treatment Resistant Depression
The researchers are trying to test the feasibility and acceptability of using
transcranial Direct Current Stimulation (tDCS) in hospitalized adult patients with
Treatment Resistant Depression (TRD), assess for any preliminary effect on depressive and
cognitive symptoms, and explore the utility of... expand
The researchers are trying to test the feasibility and acceptability of using transcranial Direct Current Stimulation (tDCS) in hospitalized adult patients with Treatment Resistant Depression (TRD), assess for any preliminary effect on depressive and cognitive symptoms, and explore the utility of biomarkers to assess response to tDCS. Type: Interventional Start Date: Oct 2024 |
Ketogenic and Nutritional Interventions for First Episode Bipolar Disorder
Mclean Hospital
Bipolar I Disorder
Psychosis
Schizoaffective Disorder
This is a randomized, controlled clinical trial to assess the effects of the ketogenic
diet in combination with treatment as usual on brain energy metabolism and psychiatric
symptoms in individuals with first episode bipolar disorder and schizoaffective disorder. expand
This is a randomized, controlled clinical trial to assess the effects of the ketogenic diet in combination with treatment as usual on brain energy metabolism and psychiatric symptoms in individuals with first episode bipolar disorder and schizoaffective disorder. Type: Interventional Start Date: Mar 2024 |
Cerebellar Modulation of Cognition in Psychosis
Mclean Hospital
Schizophrenia
Schizoaffective Disorder
Bipolar Disorder I
Psychosis
The goal of this clinical trial is to learn about cognition in psychotic disorders
(schizophrenia, bipolar disorder, and schizoaffective disorder). The main question it
aims to answer is: Can we use magnetic stimulation to change processing speed (how
quickly people can solve challenging tasks).
Participants... expand
The goal of this clinical trial is to learn about cognition in psychotic disorders (schizophrenia, bipolar disorder, and schizoaffective disorder). The main question it aims to answer is: Can we use magnetic stimulation to change processing speed (how quickly people can solve challenging tasks). Participants will be asked to perform cognitive tasks (problem-solving) and undergo brain scans before and after transcranial magnetic stimulation (TMS). TMS is a way to non-invasively change brain activity. Forms of TMS are FDA-approved to treat depression and obsessive compulsive disorder. In this study, we will use a different form of TMS to temporarily change brain activity to observe how that changes speed in problem-solving. Type: Interventional Start Date: Jul 2024 |
- Previous
- Next